Methimazole Induced Aplastic Anemia: Case Report

DOI:  https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.12105

Article Sidebar

PDF (Español (España)) HTML (Español (España)) XML (Español (España))

Published: May 8, 2024
Issue: Vol. 22 No. 2 (2024): Revista Ciencias de la Salud
Section Case Study


Keywords: Hyperthyroidism methimazole aplastic anemia antithyroid agents

Main Article Content

Authors

  Juan David Orozco Burbano
Universidad del Cauca
  Blanca Viviana Fajardo
Universidad del Cauca
Mario Ernesto Correa Correa
Universidad del Cauca
  Elvia Nohelia Muñoz
https://orcid.org/0000-0003-1156-0209
  Jesús Iván López Palechor
Clínica La estancia

Abstract

Introduction: Antithyroid drugs are one of the therapeutic alternatives in the treatment of Graves' disease. However, it can generate severe but infrequent adverse effects at the hematological level, such as aplastic anemia, which has been associated with high doses of these drugs, although with reversal of this hematological condition when the drug is withdrawn. 


Case description: A 38-year-old woman with a history of Graves' disease treated with methimazole, who consult for symptoms such as anterior epistaxis, petechiae, asthenia, and hyporexia. Pancytopenia is documented in the blood count, with a subsequent finding of bone marrow aplasia in bone marrow biopsy, without response to withdrawal of methimazole and transfusion support.


Conclusion: There are few cases of aplastic anemia associated with Methimazole without response to drug withdrawal and with fatal outcomes. Therefore, this adverse effect should be taken into account and monitored before starting this medication.

Author Biography

Elvia Nohelia Muñoz, https://orcid.org/0000-0003-1156-0209

Universidad del Cauca

How to Cite
Orozco Burbano, J. D., Fajardo, B. V. ., Correa Correa, M. E., Muñoz, E. N., & López Palechor, J. I. . (2024). Methimazole Induced Aplastic Anemia: Case Report. Revista Ciencias De La Salud, 22(2), 1–9. https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.12105
References

De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906-918. https://doi.org/10.1016/S0140-6736(16)00278-6

Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-16. https://doi.org/10.1038/nrendo.2018.18

Andrès E, Lorenzo-Villalba N, Mourot-Cottet R, Maloisel F, Tebacher M, Gottenberg J-E, et al. Severe neutropenia and agranulocytosis related to antithyroid drugs: a study of 30 cases managed in a single reference center. Medicines (Basel). 2020;7(3):15. https://doi.org/10.3390/medicines7030015

Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474-81. https://doi.org/10.1210/jc.2003-030185

Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf. 1996;15(1):53-63. https://doi.org/10.2165/00002018-199615010-00004

Cheng Y, Xia XY, Zhang W, Ren L, Tian CF, Liu D, et al. Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years. Front Endocrinol. 2023;14:1064723.

Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab. 2012;97(1):E49-53. https://doi.org/10.1210/jc.2011-2221

Thomas D, Moisidis A, Tsiakalos A, Alexandraki K, Syriou V, Kaltsas G. Antithyroid drug-induced aplastic anemia. Thyroid. 2008;18(10):1043-8. https://doi.org/10.1089/thy.2008.0097

Chen W, Chi C. Associations of HLA genotypes with antithyroid drug‐induced agranulocytosis: a systematic review and meta‐analysis of pharmacogenomics studies. Brit J Clinical Pharma. 2019;85(9):1878-87.

Biswas N, Ahn YH, Goldman JM, Schwartz JM. Aplastic anemia associated with antithyroid drugs. Am J Med Sci. 1991;301(3):190-4.

Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, Kuma K, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab. 1993;77(5):1356-60. https://doi.org/10.1210/jcem.77.5.7521347

Wijaya N, Ong-Ramos C. Methimazole-induced aplastic anemia with concomitant hepatitis in a young Filipina with Graves’ disease. J Asean Fed Endocr Soc. 2019;34(1):99-102. https://doi.org/10.15605/jafes.034.01.16

Query Statistics

Downloads

Download data is not yet available.
Publcation metrics

0




 

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Published articles are solely the authors’ responsibility and do not commit the Editorial Committee nor the Scientific Committee. The copyrights belong to the Revista Ciencias de la Salud, therefore, total or partial reproduction of the published material is forbidden, unless there is a previous authorization.